omeprazole has been researched along with mebendazole in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (57.14) | 29.6817 |
| 2010's | 4 (28.57) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Doman, TN; McGovern, SL; Seidler, J; Shoichet, BK | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Hart, CJS; Riches, A; Skinner-Adams, TS; Trenholme, KR | 1 |
| Baliharová, V; Bull, S; De Vrieze, G; Fink-Gremmels, J; Maas, RF; Skálová, L | 1 |
| Chedphaopan, J; Mitamun, W; Patrapinyokul, S; Sangkhathat, S; Wudhisuthimethawee, P | 1 |
| Gonzalez-Mendiola, R; Martínez Bohigas, D; Martínez Borque, N; Palomeque Rodríguez, T; Torrecillas Toro, M | 1 |
| Arrebola, F; Gómez-Mateos, M; González, JM; Navarro, MC; Romero, MC; Valero, A | 1 |
2 review(s) available for omeprazole and mebendazole
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Anti-
Topics: Animals; Antiprotozoal Agents; Benzimidazoles; Drug Delivery Systems; Drug Discovery; Drug Therapy, Combination; Gastrointestinal Tract; Giardia; Giardiasis; Humans; Nitroimidazoles | 2020 |
12 other study(ies) available for omeprazole and mebendazole
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
Topics: Antifungal Agents; beta-Lactamase Inhibitors; Chemical Phenomena; Chemistry, Physical; Chymotrypsin; Enzyme Inhibitors; Kinetics; Light; Malate Dehydrogenase; Models, Molecular; Molecular Conformation; Scattering, Radiation; Structure-Activity Relationship | 2003 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
The effects of mebendazole on P4501A activity in rat hepatocytes and HepG2 cells. Comparison with tiabendazole and omeprazole.
Topics: Animals; Anti-Ulcer Agents; Antinematodal Agents; Blotting, Western; Cells, Cultured; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Enzyme Induction; Enzyme Inhibitors; Hepatocytes; Humans; Mebendazole; Omeprazole; Rats; Thiabendazole; Tumor Cells, Cultured | 2003 |
Massive gastrointestinal bleeding in infants with ascariasis.
Topics: Animals; Anthelmintics; Ascariasis; Ascaris lumbricoides; Blood Transfusion; Child, Preschool; Combined Modality Therapy; Duodenal Ulcer; Fatal Outcome; Female; Gangrene; Gastrointestinal Hemorrhage; Hematemesis; Humans; Ileal Diseases; Intestinal Diseases, Parasitic; Intestinal Perforation; Intestinal Volvulus; Male; Mebendazole; Omeprazole; Peritonitis; Piperazine; Piperazines | 2003 |
Type I allergic reaction to benzimidazole antihelmintics.
Topics: Albendazole; Anthelmintics; Benzimidazoles; Drug Hypersensitivity; Female; Humans; Mebendazole; Middle Aged; Omeprazole; Skin Tests | 2007 |
Acute Anisakiasis: Pharmacological Evaluation of Various Drugs in an Animal Model.
Topics: Acute Disease; Animals; Anisakiasis; Anthelmintics; Anti-Ulcer Agents; Antinematodal Agents; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Fishes; Gastrointestinal Tract; Mebendazole; Omeprazole; Ranitidine; Rats; Rats, Wistar; Sucralfate | 2021 |